Downloads: 201

Files in This Item:
File Description SizeFormat 
j.vhri.2022.05.004.pdf502.03 kBAdobe PDFView/Open
Title: Temporal Trend in an Initial Treatment, Survival, and Medical Costs Among Patients With Lung Cancer Between 2013 and 2018 in Kyoto City, Japan
Authors: Shimamoto, Tomonari
Tateyama, Yukiko  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-4649-8428 (unconfirmed)
Kobayashi, Daisuke  KAKEN_id  orcid https://orcid.org/0000-0001-6194-9453 (unconfirmed)
Yamamoto, Keiichi
Takahashi, Yoshimitsu  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0003-4073-9945 (unconfirmed)
Ueshima, Hiroaki  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-5488-185X (unconfirmed)
Sasaki, Kosuke
Nakayama, Takeo  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-7918-6252 (unconfirmed)
Iwami, Taku  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-4150-7065 (unconfirmed)
Author's alias: 島本, 大也
立山, 由紀子
小林, 大介
山本, 景一
高橋, 由光
植嶋, 大晃
佐々木, 康介
中山, 健夫
石見, 拓
Keywords: administrative data
Japan
lung cancer
medical cost
Issue Date: Sep-2022
Publisher: Elsevier BV
International Society for Health Economics and Outcomes Research
Journal title: Value in Health Regional Issues
Volume: 31
Start page: 163
End page: 168
Abstract: OBJECTIVES: This study aimed to identify the variation of treatment contents and outcomes and economic burden of lung cancer among the elderly population in Japan. METHODS: New-onset primary lung cancer from April 2013 to March 2019 were identified by using the Kyoto City administrative database for National Health Insurance and Advanced Elderly Medical Service System. Patient characteristics, initial treatment, medical costs, and deaths were analyzed. Continuous variables were calculated using standard descriptive statistical methods. RESULTS: A total of 4845 people who were diagnosed as having lung cancer and received any treatment between 2013 and 2018 were included in the study. The average age of patients was 73 to 74 years for a 6-year study period. The proportion of patients who received surgery, drug therapy, and radiation therapy as initial treatment was 31% to 42%, 36% to 44%, and 21% to 24%, respectively. Healthcare costs increased between fiscal year (FY) 2014 and FY 2018, with a particularly significant increase of 340 million for drug therapy, whereas the mortality rate in <2-year follow-up decreased from 42.7% in FY 2013 to 368% in FY 2016. CONCLUSIONS: This cross-sectional study demonstrated that the improvement in the survival rate and proportion of surgery as an initial treatment was increased whereas drug therapy decreased and medical costs increased among patients with lung cancer over time. Based on these results, it is necessary to implement sustainable healthcare measures with a consideration of cost-effectiveness.
Description: 2013年から2018年にかけた京都市における肺がん患者の初期治療、医療費及び生存割合の変化. 京都大学プレスリリース. 2022-07-28.
Rights: © 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.
This is an open access article under the Creative Commons Attribution 4.0 International license.
URI: http://hdl.handle.net/2433/275670
DOI(Published Version): 10.1016/j.vhri.2022.05.004
PubMed ID: 35777173
Related Link: https://www.kyoto-u.ac.jp/ja/research-news/2022-07-28
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons